{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:12:54Z","timestamp":1790957574131,"version":"4.1.0"},"reference-count":24,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T00:00:00Z","timestamp":1650326400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Correvio","award":["FC81A543-5FE5-4B8F-9C75-0F2C788BF031"],"award-info":[{"award-number":["FC81A543-5FE5-4B8F-9C75-0F2C788BF031"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Dalbavancin is emerging as a promising alternative in the ambulant treatment of gram-positive infections that require long-term antibiotic treatment such as osteomyelitis, prosthetic joint infections, and endocarditis. The aim of the current study was to develop and validate a simple, rapid, and cost-effective high-performance liquid chromatography\u2013ultraviolet spectrometry (HPLC\u2013UV) method for the quantification of dalbavancin. Sample clean-up included a protein precipitation protocol, followed by chromatographic separation on a reverse phase HPLC column (C-18) with gradient elution of the mobile phase. Quantification was performed with the internal standard (caffeine) method. Linear relationships between peak area responses and drug concentrations were obtained in the range of 12.5\u2013400 mg\/L. The variation coefficient of precision and the bias of accuracy (both inter- and intraday) were less than 10%. The limit of quantification (LOQ) was 12.5 mg\/L. The simple and reliable HPLC\u2013UV assay described is a powerful tool for routine therapeutic drug monitoring (TDM) of dalbavancin in human serum in clinical laboratories. With a total process time of approximately 20 min, it allows for accurate and selective quantification up to the expected pharmacokinetic peak concentrations. The method was successfully used to analyze subsequent serum samples of three patients and showed good performance in monitoring serum levels.<\/jats:p>","DOI":"10.3390\/antibiotics11050541","type":"journal-article","created":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T22:07:26Z","timestamp":1650406046000},"page":"541","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Validation and Application of an HPLC-UV Method for Routine Therapeutic Drug Monitoring of Dalbavancin"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4288-1745","authenticated-orcid":false,"given":"Ute","family":"Chiriac","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Heidelberg University Hospital, 69120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Rau","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, General Hospital of Heidenheim, 89522 Heidenheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9482-5094","authenticated-orcid":false,"given":"Otto R.","family":"Frey","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, General Hospital of Heidenheim, 89522 Heidenheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anka C.","family":"R\u00f6hr","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, General Hospital of Heidenheim, 89522 Heidenheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Klein","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Medical Microbiology and Hospital Hygiene, Heidelberg University Hospital, 69120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna L.","family":"Meyer","sequence":"additional","affiliation":[{"name":"Department of Cardiac Surgery, Heidelberg University Hospital, 69120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1926-0585","authenticated-orcid":false,"given":"Benedict","family":"Morath","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Heidelberg University Hospital, 69120 Heidelberg, Germany"},{"name":"Cooperation Unit Clinical Pharmacy, Heidelberg University, 69120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,4,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1310480","article-title":"Once-weekly dalbavancin versus daily conventional therapy for skin infection","volume":"370","author":"Boucher","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/cid\/civ982","article-title":"A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection","volume":"62","author":"Dunne","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.2147\/DDDT.S313756","article-title":"Real-World Use of Dalbavancin in the Era of Empowerment of Outpatient Antimicrobial Treatment: A Careful Appraisal Beyond Approved Indications Focusing on Unmet Clinical Needs","volume":"15","author":"Gatti","year":"2021","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/cpdd.695","article-title":"Dalbavancin Population Pharmacokinetic Modeling and Target Attainment Analysis","volume":"9","author":"Carrothers","year":"2020","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"7833","DOI":"10.1128\/AAC.01717-15","article-title":"Impact of Glycopeptide Resistance in Staphylococcus aureus on the Dalbavancin In Vivo Pharmacodynamic Target","volume":"59","author":"Lepak","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_6","unstructured":"EUCAST (2022, January 24). Antimicrobial Wild Type Distributions of Microorganisms for Dalbavancin. Available online: https:\/\/mic.eucast.org\/search\/."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1128\/AAC.04550-14","article-title":"Extended-duration dosing and distribution of dalbavancin into bone and articular tissue","volume":"59","author":"Dunne","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1016\/j.jchromb.2011.07.027","article-title":"Dalbavancin: Quantification in human serum and urine by a new improved high performance liquid chromatography-tandem mass spectrometry method","volume":"879","author":"Demers","year":"2011","journal-title":"J. Chromatogr. B"},{"key":"ref_9","unstructured":"Schmitt, G., Herbold, M., and Peters, F. (2003). Methodenvalidierung im Forensisch-Toxikologischen Labor: Auswertung von Validierungsdaten Nach den Richtlinien der GTFCh mit VALISTAT, Arvecon GmbH."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e01024-19","DOI":"10.1128\/AAC.01024-19","article-title":"Epithelial Lining Fluid and Serum Concentrations of Dalbavancin in Healthy Adults after a Single 1500-Milligram Infusion","volume":"63","author":"Rappo","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"ii25","DOI":"10.1093\/jac\/dki008","article-title":"Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide","volume":"55","author":"Dorr","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"ofz427","DOI":"10.1093\/ofid\/ofz427","article-title":"Serum Bactericidal Activity Levels Monitor to Guide Intravenous Dalbavancin Chronic Suppressive Therapy of Inoperable Staphylococcal Prosthetic Valve Endocarditis: A Case Report","volume":"6","author":"Spaziante","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e26253","DOI":"10.1097\/MD.0000000000026253","article-title":"Personalized ss-lactam dosing in patients with coronavirus disease 2019 (COVID-19) and pneumonia: A retrospective analysis on pharmacokinetics and pharmacokinetic target attainment","volume":"100","author":"Chiriac","year":"2021","journal-title":"Medicine"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1177\/0091270008330162","article-title":"Pharmacokinetics of dalbavancin in patients with renal or hepatic impairment","volume":"49","author":"Marbury","year":"2009","journal-title":"J. Clin. Pharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1128\/AAC.02176-12","article-title":"Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection","volume":"57","author":"Brown","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/d41586-018-03267-5","article-title":"When antibiotics turn toxic","volume":"555","author":"Marchant","year":"2018","journal-title":"Nature"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1111\/jgs.14718","article-title":"Is Polypharmacy Associated with Frailty in Older People? Results from the ESTHER Cohort Study","volume":"65","author":"Saum","year":"2017","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"572","DOI":"10.5414\/CP203372","article-title":"Pill-count and the arithmetic of risk: Evidence that polypharmacy is a health status marker rather than a predictive surrogate for the risk of adverse drug events","volume":"56","author":"Haefeli","year":"2018","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.cger.2012.01.008","article-title":"Medication adherence to multidrug regimens","volume":"28","author":"Marcum","year":"2012","journal-title":"Clin. Geriatr. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1001\/archinte.165.10.1147","article-title":"Predictors of adherence with antihypertensive and lipid-lowering therapy","volume":"165","author":"Chapman","year":"2005","journal-title":"Arch. Intern. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciy745","article-title":"2018 Infectious Diseases Society of America Clinical Practice Guideline for the Management of Outpatient Parenteral Antimicrobial Therapy","volume":"68","author":"Norris","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1093\/jac\/dkz343","article-title":"Outpatient parenteral antimicrobial therapy: Updated recommendations from the UK","volume":"74","author":"Chapman","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: A Position Paper","volume":"46","author":"Alffenaar","year":"2020","journal-title":"Intensive Care Med."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/11\/5\/541\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:56:51Z","timestamp":1760137011000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/11\/5\/541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,19]]},"references-count":24,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["antibiotics11050541"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics11050541","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,19]]}}}